Lingling Chen1, Sujie Ni2, Mei Li2, Chaoyan Shen2, Zhipeng Lin1, Yu Ouyang3, Fei Xia4, Li Liang2, Wenyan Jiang2, Runzhou Ni5, Jianguo Zhang6. 1. Department of Gastroenterology, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu, China. 2. Department of Medical Oncology, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu, China. 3. Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, Jiangsu, China. 4. Department of Radiology, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu, China. 5. Department of Gastroenterology, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu, China. nrz0513@sina.cn. 6. Department of Pathology, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu, China. zhjg226@sina.com.
Abstract
BACKGROUND: BCCIP was originally identified as a BRCA2 interacting protein in humans and Ustilago maydis. It had low expression in some human cancer tissues. However, recent research indicated that many caretaker genes are also necessary for cell viability and their expression could contribute to tumor progression. AIM: To characterize whether BCCIP is a caretaker gene in esophageal squamous cell carcinoma (ESCC). METHODS: Western blotting and immunohistochemistry were used to measure the expression of BCCIP β. In vitro studies were used to verify the effects of BCCIP β in Eca109 cells. RESULTS: Expression of BCCIP β was notably higher in tumor tissues of ESCC and Eca 109 cells. Meanwhile, the immunohistochemistry stain revealed that BCCIP β was positively correlated with clinical pathologic variables such as tumor size and tumor grade, as well as Ki-67, and prompted poor prognosis. In vitro studies such as starvation and refeeding assay along with BCCIP β-shRNA transfection assay demonstrated that BCCIP β expression promoted proliferation of ESCC cells. In addition, BCCIP β downregulation by silencing RNA significantly decreased the rate of colony formation, alleviated cellular apoptosis and increased the chemosensitivity of cisplatin. CONCLUSIONS: This research first put forward that BCCIP β is an oncogene in human ESCC and contributes to the poor outcome of the deadly disease.
BACKGROUND:BCCIP was originally identified as a BRCA2 interacting protein in humans and Ustilago maydis. It had low expression in some humancancer tissues. However, recent research indicated that many caretaker genes are also necessary for cell viability and their expression could contribute to tumor progression. AIM: To characterize whether BCCIP is a caretaker gene in esophageal squamous cell carcinoma (ESCC). METHODS: Western blotting and immunohistochemistry were used to measure the expression of BCCIP β. In vitro studies were used to verify the effects of BCCIP β in Eca109 cells. RESULTS: Expression of BCCIP β was notably higher in tumor tissues of ESCC and Eca 109 cells. Meanwhile, the immunohistochemistry stain revealed that BCCIP β was positively correlated with clinical pathologic variables such as tumor size and tumor grade, as well as Ki-67, and prompted poor prognosis. In vitro studies such as starvation and refeeding assay along with BCCIP β-shRNA transfection assay demonstrated that BCCIP β expression promoted proliferation of ESCC cells. In addition, BCCIP β downregulation by silencing RNA significantly decreased the rate of colony formation, alleviated cellular apoptosis and increased the chemosensitivity of cisplatin. CONCLUSIONS: This research first put forward that BCCIP β is an oncogene in human ESCC and contributes to the poor outcome of the deadly disease.
Authors: You Wang; Yingying Wang; Jingying Xiang; Fang Ji; Yan Deng; Chunhui Tang; Shuyun Yang; Qinghua Xi; Rong Liu; Wen Di Journal: Cancer Lett Date: 2013-09-07 Impact factor: 8.679